Skip to main content
. 2022 Aug 23;8:96. doi: 10.1038/s41523-022-00470-6

Fig. 1. Fulvestrant resistant BC cell lines express ERα-LBD, a novel estrogen receptor α isoform.

Fig. 1

a, b Western blot analysis of estrogen receptor alpha (ERα) protein expression in breast cancer (BC) cell lines. Cells were cultured for 24 h in the presence of vehicle (−) or fulvestrant 1 µM (+) before lysis. Vehicle = DMSO. ERα protein expression was normalized against β-actin. Increasing levels of hormonal therapy resistance (HTR) are indicated. A potential smaller ERα isoform is indicated in blue. c Comparison between ERα-LBD and ERα-FL (full-length): domains (AF-1, transcription Activation Function-1; DBD, DNA Binding Domain; Hinge; LBD, Ligand Binding Domain; AF-2, transcription Activation Function-2), amino acid (AA) number, molecular weight, 3-D structure prediction (Phyre2). d ERα protein stability assay. ERα-LBD and ERα-FL protein levels were analyzed by western blot in MDA-MB-231 and MCF-7 cells, respectively. Protein samples were collected at different time points (2-24 h), after treatment. Physiological levels of E2 (pM range) were present in all samples, except samples in lane 3 and 4. Vehicle DMSO, CSS charcoal-stripped serum. Source data are provided as a Source Data file.